Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis

Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis

ObjectiveTo ascertain the changes of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) values in relapsing–remitting multiple sclerosis (RRMS) patients treated with ocrelizumab and their association with treatment response.MethodsMulticenter prospective study includi...

Full description

Bibliographic Details
Main Authors: Fernando Rodríguez-Jorge, José Ignacio Fernández-Velasco, Noelia Villarrubia, Julia Gracia-Gil, Eva Fernández, Virginia Meca-Lallana, Carolina Díaz-Pérez, Susana Sainz de la Maza, Eva María Pacheco, Ana Quiroga, Lluis Ramió-Torrentà, Sergio Martínez-Yélamos, Laura Bau, Enric Monreal, Ana López-Real, Alexander Rodero-Romero, Laura Borrega, Santiago Díaz, Pablo Eguía, Mercedes Espiño, Juan Luis Chico-García, Francisco Javier Barrero, María Luisa Martínez-Ginés, José Manuel García-Domínguez, Soraya De la Fuente, Irene Moreno, Raquel Sainz-Amo, M. Alba Mañé-Martínez, Ana Caminero, Fernando Castellanos-Pinedo, Ana Gómez López, Andrés Labiano-Fontcuberta, Lucía Ayuso, Rossana Abreu, Miguel Ángel Hernández, José Meca-Lallana, Lorena Martín-Aguilar, Alfonso Muriel García, Jaime Masjuan, Lucienne Costa-Frossard, Luisa María Villar
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Immunology
Subjects:
multiple sclerosis
ocrelizumab
neurofilament light chain
glial fibrillary acidic protein
serum biomarkers
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1480676/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1480676/full

Similar Items